Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
NBC 7 San Diego14d
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...
Business Insider7d
Eli Lilly & Co (LLY) Receives a Buy from Bank of America Securities
Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Pfizer. Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average ...